<DOC>
	<DOCNO>NCT00323050</DOCNO>
	<brief_summary>The purpose study evaluate immunogenicity , safety reactogenicity booster dose Hib-MenC conjugate vaccine give healthy subject age 13 14 month prim three dos Hib-MenC compare booster dose Infanrix hexa give subject prim three dos Infanrix hexa Meningitec .</brief_summary>
	<brief_title>Study Booster Dose Hib-MenC Conjugate Vaccine v Infanrix Hexa When Given 14 Month Old Subjects</brief_title>
	<detailed_description>The study open Infanrix hexa serve active control . Subjects receive one vaccine dose either Hib-MenC Infanrix hexa , 2 blood sample take : one month vaccination . Subjects receive booster dose Hib-MenC prim 3 dos Infanrix penta + Hib-MenC 2 dose NeisVac-C Infanrix hexa / Infanrix IPV/Hib .</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion criterion : Healthy male female , include , 13 14 month age Having participate primary vaccination study 217744/097 . Exclusion criterion : Previous vaccination OR history OR know exposure diphtheria , tetanus , pertussis , hepatitis B , polio , H. influenzae type b ( Hib ) and/or meningococcal serogroup C disease except within framework study 217744/097 Any confirm suspected immunosuppressive immunodeficient condition , include human immunodeficiency virus ( HIV ) infection A family history congenital hereditary immunodeficiency History neurologic disorder seizure</criteria>
	<gender>All</gender>
	<minimum_age>13 Months</minimum_age>
	<maximum_age>14 Months</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>